Sherene Loi MD
LightNews LightNews
banner
loisher.bsky.social
Sherene Loi MD
@loisher.bsky.social
240 followers 89 following 15 posts
Professor Medical Oncologist; Breast cancer specialist; Group leader. Peter MacCallum Cancer Centre, Melbourne Australia;
ETOP-IBCSG
Posts Replies Media Videos
Pinned
loisher.bsky.social
Sherene Loi MD @loisher.bsky.social · Jan 12
HNY everyone! Our latest review @natrevcancer.bsky.social on the #breastcancer immune microenvironment is pinned here. Looking fwd to a very exciting 2025.
rdcu.be/d51vW
Towards targeting the breast cancer immune microenvironment
Nature Reviews Cancer - In this Review, Harris et al. summarize the dynamic changes of the immune breast tumour microenvironment (TME) that take place during disease progression and in response to...
rdcu.be
Reposted by Sherene Loi MD
drsgraff.bsky.social
The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social
May 30, 2025 at 8:30 PM
loisher.bsky.social
Pleased to be part of these elections!
May 30, 2025 at 10:39 PM
Reposted by Sherene Loi MD
myesmo.bsky.social
In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.

Full article in the #ESMODailyReporter

🔗 ow.ly/rtbo50VSyiN
May 14, 2025 at 1:41 PM
Reposted by Sherene Loi MD
oncodaily.bsky.social
DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer
@myesmo.bsky.social @loisher.bsky.social

oncodaily.com/science/diam...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25
DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2 Positive Breast Cancer - OncoDaily
Dual checkpoint blockade with tremelimumab + durvalumab shows promise in HER2-positive advanced breast cancer with trastuzumab resistance in the DIAmOND trial at ESMO 2025.
oncodaily.com
May 17, 2025 at 2:36 PM
loisher.bsky.social
🎈🎈🎈news day for #HER2 pos #breastcancer. Will look fwd to seeing the HR and comparable toxicity profiles
www.astrazeneca.com/media-centre...
Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive met...
www.astrazeneca.com
April 22, 2025 at 11:43 PM
Reposted by Sherene Loi MD
ascopost.bsky.social
Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer?
A phase II study led by Dr. Sherene Loi explores this critical question.
Read more: ascopost.com/news/march-2...
#TripleNegativeBreastCancer #Immunotherapy
Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation
The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in patients with ear...
ascopost.com
April 16, 2025 at 2:55 PM
Reposted by Sherene Loi MD
drsgraff.bsky.social
Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025
March 12, 2025 at 3:21 PM
Reposted by Sherene Loi MD
bigxresearch.bsky.social
#SGBCC2025 - The 19th St.Gallen International #BreastCancer Conference 2025 is almost here!💡 Key BIG 🔬 experts like Drs. Giuseppe Curigliano,
@loisher.bsky.social, @tanjaspanic.bsky.social, & more will be there. Don't miss their insights! @oncoalert.bsky.social #bcsm
March 5, 2025 at 4:02 PM
loisher.bsky.social
@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳
Great discussion for #breastcancer #lungcancer #GIcancers
February 22, 2025 at 3:08 AM
Reposted by Sherene Loi MD
marleenkok.bsky.social
Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️
February 7, 2025 at 9:47 AM
loisher.bsky.social
🚩pleased to share our latest "Genomic Characterisation and Prognostic Significance of HER2–Low, HR+, Early #Breastcancer From the BIG 1-98 and SOFT Clinical Trials" #bcsm using centrally reviewed HER2 IHC from 2 large clinical trials #IBCSG @oncoalert.bsky.social 👏
ascopubs.org/doi/10.1200/...
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials | JCO P...
PURPOSETo investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characte...
ascopubs.org
February 10, 2025 at 1:50 AM
loisher.bsky.social
🎈our recent collaborative review on “Complexities of Cancer” highlighted here 👏👏👏 🙏 @cp-cell.bsky.social as well as many other seminal articles- well worth a look 👀 @oncoalert.bsky.social
cp-cell.bsky.social Cell - a Cell Press journal @cp-cell.bsky.social · Jan 23
As we wrap up our year-long celebration of Cell’s 50th anniversary, we present “Cell Line: 2014–2024,” a timeline highlighting a set of exceptional scientific works—both landmark papers and essential reviews—published in the journal. www.cell.com/action/showP...
Screen capture of a Timeline article of significant papers published in Cell during the period from 2014 to 2024. The link in the post provides access to a PDF of the full article.
February 8, 2025 at 12:37 AM
loisher.bsky.social
Remembering Jose Baselga and the superstar 👏⭐️ he was
February 5, 2025 at 9:55 PM
loisher.bsky.social
summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...
rdcu.be
February 4, 2025 at 9:32 PM
loisher.bsky.social
🎈Adjuvant Atezo for fully resected #TNBC #breastcancer is of NO benefit. We’ll see soon results from SWOG trial in re post neoadjuvant (w/o IO). Exposure to antigen and draining LN seems v. important for ICB efficacy. @oncoalert.bsky.social #bcsm
bigxresearch.bsky.social Breast International Group @bigxresearch.bsky.social · Jan 30
🚨 The final analysis of the phase 3 #ALEXANDRA/IMpassion030 study on adding atezolizumab to post-op chemo for high-risk early-stage #TNBC is out in @jama.com, contributing to a greater understanding of immunotherapy in #breastcancer👉 jamanetwork.com/journals/jam...
@mignatiadis.bsky.social
January 31, 2025 at 2:49 AM
loisher.bsky.social
➡️➡️ very exciting news for estrogen receptor + #breastcancer- a subset is very immunogenic - this data changes the way we think about T cell immunosurveillance in this BC subtype
👏👏👏
petermaccc.bsky.social Peter MacCallum Cancer Centre @petermaccc.bsky.social · Jan 22
A Peter Mac international clinical trial led by @loisher.bsky.social has shown adding #immunotherapy drug nivolumab + chemo before surgery can dramatically improve #breastcancer cure rates.

On the front page of today's Herald Sun or more here: www.petermac.org/about-us/new...
January 22, 2025 at 9:15 AM
Reposted by Sherene Loi MD
elisabettabonzano.bsky.social
📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social
January 19, 2025 at 11:11 AM
loisher.bsky.social
Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials
January 16, 2025 at 11:16 PM
loisher.bsky.social
Great fun discussing #breastcsncer #immunotherapy in #japan #nagoya 🙏
January 15, 2025 at 12:31 PM
Reposted by Sherene Loi MD
petermaccc.bsky.social
We are incredibly proud to announce that five Peter Mac researchers have been named in Clarivate's top 1% most cited researchers worldwide for 2024.

Read more: www.petermac.org/about-us/new...
December 3, 2024 at 4:02 AM
loisher.bsky.social
HNY everyone! Our latest review @natrevcancer.bsky.social on the #breastcancer immune microenvironment is pinned here. Looking fwd to a very exciting 2025.
rdcu.be/d51vW
Towards targeting the breast cancer immune microenvironment
Nature Reviews Cancer - In this Review, Harris et al. summarize the dynamic changes of the immune breast tumour microenvironment (TME) that take place during disease progression and in response to...
rdcu.be
January 12, 2025 at 12:03 PM
loisher.bsky.social
#sabcs24
HR+HER2+ #breastcancer now finally its own entity 👏👏👏
December 12, 2024 at 4:23 PM
loisher.bsky.social
#sabcs24
State of the Art session speakers Immune bio markers #til thanks to @balkolab @psharmab
December 12, 2024 at 6:56 AM